In biologics manufacturing, success depends on product reproducibility. Through sophisticated cell line development, cell culture manufacturing and quality control processes, AbbVie helps partners overcome the complexity of large molecule manufacturing to deliver consistent drug performance.

Our mammalian modality expertise includes:

• Monoclonal antibodies (mAb)

• Multispecific mAbs

• Fusion proteins

• Bispecific and trispecific antibodies

• Antibody drug conjugates (ADC)

With patients' lives on the line, biologics must be safe, reliable and consistent. At AbbVie Contract Manufacturing, we understand that speed-to-market is imperative for large molecule drugs—but so are efficiency and cost containment. Achieving these goals depends largely on the quality of the cell line at the heart of the process, which is tied directly to the CDMO partner you choose.

In biologics manufacturing, success is measured largely by product reproducibility. Through sophisticated cell line development, cell culture manufacturing and quality control processes, we can help you overcome the complexity of large molecule manufacturing to deliver consistent drug performance. Let our excellent track record of biopharmaceutical process development set the foundation for a sustainable, reliable biologics program and ongoing supply of your drug product.

AbbVie offers mammalian cell culture services from facilities in the US, and Europe, providing geographic flexibility and supply chain redundancy for global commercial programs.

Worcester, MA, USA

The Worcester facility is AbbVie's center of excellence for biologics, with 38,000L of mammalian manufacturing capacity across six dedicated suites. The site offers decades of commercial expertise and an experienced workforce of nearly 1,000 R&D and operations professionals. Capabilities include mAb, bispecific and fusion protein manufacturing, plus antibody drug conjugation services.

Barceloneta, Puerto Rico (Large Molecule)

The Puerto Rico biologics facility has supplied medicines worldwide since 2007 with a proven global regulatory track record. The site features two cell culture suites with 6,000L to 12,000L configurations, downstream purification with full QC/QA support and aseptic prefilled syringe manufacturing.

Martillac, France (MBM)

The Martillac MBM facility, offers mammalian biologics drug substance development and cGMP manufacturing in Martillac, France, near Bordeaux. As a global biopharmaceutical partner, we can support your molecule from pre-clinical development through commercial supply at a single biologics drug substance manufacturing facility.

AbbVie provides comprehensive analytical support for mammalian cell culture programs:

• HPLC (SEC, IEX, affinity, reverse phase)

• Host cell protein analysis

• Electrophoresis (CE, IEF, SDS-PAGE)

• ELISA

• Peptide structure determination (LC, MS)

• Oligosaccharide analysis

• DNA quantification and identification (PCR)

• Spectrophotometry (FT-IR, UV VIS)

• Bioburden and endotoxin testing

AbbVie is in a unique position to support your extended supply chain from drug substance to drug product. We also support all elements of antibody drug conjugates within a single quality and operational network as one of the industry's leading ADC innovators.

As a global pharmaceutical company, AbbVie provides extensive expertise and a unified quality and operational network. Our company includes over 30,000 professionals at facilities around the world that can deliver solutions and reliable supply of a wide array of drug components at any phase of development up to and including commercial lifecycle management.